Epigenetic reprogramming sensitizes CML stem cells to combined EZH2 and tyrosine kinase inhibition

A major obstacle to curing chronic myeloid leukaemia (CML) is residual disease maintained by tyrosine kinase inhibitor (TKI)-persistent leukemic stem cells (LSCs). These are BCR-ABL1 kinase-independent (1, 2), refractory to apoptosis (3, 4) and serve as a reservoir to drive relapse or TKI-resistance...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Discov
Auteurs principaux: Scott, Mary T., Korfi, Koorosh, Saffrey, Peter, Hopcroft, Lisa E.M., Kinstrie, Ross, Pellicano, Francesca, Guenther, Carla, Gallipoli, Paolo, Cruz, Michelle, Dunn, Karen, Jorgensen, Heather G., Cassels, Jennifer E., Hamilton, Ashley, Crossan, Andrew, Sinclair, Amy, Holyoake, Tessa L., Vetrie, David
Format: Artigo
Langue:Inglês
Publié: 2016
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538532/
https://ncbi.nlm.nih.gov/pubmed/27630125
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-16-0263
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires